Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02498379 · ClinicalTrials.gov registry record · Early Phase 1
PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02498379 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 8 participants.
The verdict
NCT02498379, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is designed to assess the safety, biodistribution and dosimetry of the novel atherosclerotic imaging PET radiotracer, Cu\[64\]-25%-CANF-Comb.
Interventions
- DRUG Cu[64]-25%CANF-Comb
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-10 |
| Est. Completion | 2015-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02498379
The ClinicalTrials.gov registry entry for NCT02498379 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cu[64]-25%CANF-Comb is the first listed.
NCT02498379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02498379 about?
NCT02498379 is a clinical study titled "PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)". This study is designed to assess the safety, biodistribution and dosimetry of the novel atherosclerotic imaging PET radiotracer, Cu\[64\]-25%-CANF-Comb.
What is the current status of trial NCT02498379?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2014-10. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02498379?
The interventions under investigation include: Cu[64]-25%CANF-Comb (DRUG).
Who is sponsoring clinical trial NCT02498379?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.